内皮细胞特异性分子-1在血液系统恶性肿瘤危重症患者中的研究
该前瞻性多中心队列研究纳入法国和比利时17个ICU的744例连续血液系统恶性肿瘤危重症患者,另设72例无血液系统恶性肿瘤的脓毒症危重患者和276名健康对照。ICU入院时总Endocan中位浓度为4.46(2.7-7.8)ng/mL;化疗后患者Endocan更高(4.7 vs 3.7 ng/mL,p=0.002);急性呼吸衰竭中药物性肺毒性者Endocan高于其他病因(p=0.038)。总Endocan>4.46 ng/mL与更高的肾脏替代治疗、机械通气和血管升压药需求相关;多因素分析显示入院总Endocan与ICU死亡率独立相关(OR 1.39,95%CI 1.06-1.83,p=0.018)。作者认为需要研究基于Endocan在急诊或血液病房进行风险分层,以识别可能从早期ICU管理中获益的患者。
要点
- 在744例血液系统恶性肿瘤危重症患者中,ICU入院时总Endocan中位浓度为4.46(2.7-7.8)ng/mL。
- 总Endocan>4.46 ng/mL与ICU期间更高的肾脏替代治疗需求(p=0.006)、机械通气需求(p=0.01)和血管升压药需求(p<0.0001)相关。
- 多因素分析显示,入院时总Endocan与ICU死亡率独立相关(OR 1.39,95%CI 1.06-1.83,p=0.018)。
- 14 kDa Endocan肽段对死亡率和生命支持治疗需求的预测价值低于总Endocan。
- 血液系统恶性肿瘤危重症患者Endocan高于健康对照(p<0.0001),但低于无血液系统恶性肿瘤的脓毒症危重患者(p=0.005)。
适用人群与场景
- 法国和比利时17个ICU连续纳入的744例血液系统恶性肿瘤危重症患者。
- 对照包括72例无血液系统恶性肿瘤的脓毒症危重患者和276名健康受试者。
研究设计与关键结果
- 研究类型为前瞻性多中心队列研究,纳入744例血液系统恶性肿瘤危重症患者、72例无血液系统恶性肿瘤的脓毒症危重患者和276名健康受试者,共17个ICU。
- ICU入院时总Endocan中位浓度为4.46(2.7-7.8)ng/mL;入住ICU前接受化疗者Endocan为4.7(2.8-8.1)ng/mL,未化疗者为3.7(2.5-6.3)ng/mL(p=0.002)。
- 急性呼吸衰竭患者中,药物性肺毒性者Endocan水平高于其他病因者(p=0.038)。
- 总Endocan>4.46 ng/mL与ICU期间更高的肾脏替代治疗累积概率(p=0.006)、更高的机械通气需求(p=0.01)和更高的血管升压药需求(p<0.0001)相关。
- 多因素分析显示,入院时总Endocan与ICU死亡率独立相关(OR 1.39,95%CI 1.06-1.83,p=0.018)。
- 14 kDa Endocan肽段对死亡率和生命支持治疗需求的预测价值低于总Endocan。
- 血液系统恶性肿瘤危重症患者Endocan高于健康受试者(p<0.0001),但低于无血液系统恶性肿瘤的脓毒症危重患者(p=0.005)。
证据类型、等级与局限
- 证据类型:前瞻性多中心队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,需要研究基于Endocan浓度在急诊或血液病房对患者进行风险分层,以识别可能从早期ICU管理中获益的患者。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To assess whether serum concentration of endothelial cell-specific molecule-1 (Endocan) at ICU admission is associated with the use of ICU resources and outcomes in critically ill hematology patients.
DESIGN: Prospective multicenter cohort study.
SETTING: Seventeen ICUs in France and Belgium.
PATIENTS: Seven hundred forty-four consecutive critically ill hematology patients; 72 critically ill septic patients without hematologic malignancy; 276 healthy subjects.
MEASUREMENTS AND MAIN RESULTS: Median total endocan concentrations were 4.46 (2.7-7.8) ng/mL. Endocan concentrations were higher in patients who had received chemotherapy before ICU admission (4.7 [2.8-8.1] ng/mL vs. 3.7 [2.5-6.3] ng/mL [p = 0.002]). In patients with acute respiratory failure, endocan levels were increased in patients with drug-induced pulmonary toxicity compared with other etiologies (p = 0.038). Total endocan levels higher than 4.46 ng/mL were associated with a higher cumulative probability of renal replacement therapy requirement (p = 0.006), a higher requirement of mechanical ventilation (p = 0.01) and a higher requirement of vasopressors throughout ICU stay (p < 0.0001). By multivariate analysis, total endocan levels at admission were independently associated with ICU mortality (odds ratios, 1.39; 95% CI, 1.06-1.83; p = 0.018). The predictive value of endocan peptide fragments of 14 kDa in terms of mortality and life-sustaining therapies requirement was inferior to that of total endocan. Endocan levels were higher in critically ill hematology patients compared with healthy subjects (p < 0.0001) but lower than endocan values in critically ill septic patients without hematologic malignancy (p = 0.005) CONCLUSIONS:: Serum concentrations of endocan at admission are associated with the use of ICU resources and mortality in critically ill hematology patients. Studies to risk-stratify patients in the emergency department or in the hematology wards based on endocan concentrations to identify those likely to benefit from early ICU management are warranted.
参考来源
- Zafrani L, Resche-Rigon M, De Freitas Caires N, et al. Endothelial Cell-Specific Molecule-1 in Critically Ill Patients With Hematologic Malignancy. Crit Care Med. 2018. PMID: 29474336. doi:10.1097/CCM.0000000000002934
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。